NCT05717920CompletedPhase 2
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
The ADRO Trial: An Adaptive, 2-Part, Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Adults With Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 4 Nov 2024
Brief summary (registry, in English)
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- First submitted
- 25 Jan 2023
- Start date
- 15 Feb 2023
- Primary completion date
- 21 Nov 2023
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT05717920
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 8
- From 15 Feb 2023 to the primary completion date, 21 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of any unstable chronic diseases/conditions, clinically significant abnormalities, or findings, that in the opinion of the Investigator, could compromise subject safety or affect the conduct of the trial
Lab values
- Presence of clinically significant kidney disease or an estimated gloverular filtration rate (eGFR) of less than or equal to 45 milliliters/min/1.73 m2 during screening
Who the study is looking for
- Adults ≥18 years of age
- History of atopic dermatitis, according to American Academy of Dermatology criteria, that has been present for at least 6 months
- Mild, moderate, or severe atopic dermatitis, defined as an IGA score of ≥2 at Baseline
- Not pregnant, breastfeeding, or lactating and agree to use a highly effective method of acceptable contraceptive for the trial duration, if applicable
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bexley Dermatology Research Coordinator of this site? Confirm its status | Bexley | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.